BlackRock Investment Management’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

BlackRock Investment Management’s Portfolio CNCE Stock Details CNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$736K	Hold	71,478	–	–	﹤0.01%	2872
2016 Q3	$723K	Buy	71,478 +6,946	+11%	+$75.9K	﹤0.01%	2857
2016 Q2	$725K	Buy	64,532 +8,601	+15%	+$110K	﹤0.01%	2845
2016 Q1	$764K	Buy	55,931 +1,109	+2%	+$16K	﹤0.01%	2664
2015 Q4	$1.04M	Buy	54,822 +443	+0.8%	+$9.63K	﹤0.01%	2573
2015 Q3	$1.02M	Buy	54,379 +41	+0.1%	+$697	﹤0.01%	2584
2015 Q2	$809K	Buy	54,338 +52,996	+3,949%	+$807K	﹤0.01%	2922
2015 Q1	$20K	Buy	1,342 +236	+21%	+$3.29K	﹤0.01%	3447
2014 Q4	$15K	Hold	1,106	–	–	﹤0.01%	3539
2014 Q3	$14K	Buy	1,106 +40	+4%	+$388	﹤0.01%	3542
2014 Q2	$11K	Sell	1,066 -15,986	-94%	-$154K	﹤0.01%	3611
2014 Q1	$229K	Buy	+17,052	New	+$241K	﹤0.01%	3217

Other funds holding CNCE

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

SAM

Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return

BlackRock Investment Management's CNCE Position: Q4 2016 in Review

BlackRock Investment Management held its Concert Pharmaceuticals, Inc. (CNCE) position steady in Q4 2016 at 71,478 shares worth $736K. The position accounts for ﹤0.01% of the portfolio, ranked #2872.

BlackRock Investment Management first reported a position in CNCE in Q1 2014 and has held it in 12 quarters since. The position peaked at $1.04M in Q4 2015. 89 funds tracked by Wall St. Rank hold CNCE as of Q4 2016.

BlackRock Investment Management held 71,478 shares of Concert Pharmaceuticals, Inc. worth $736K as of Q4 2016.
BlackRock Investment Management left its Concert Pharmaceuticals, Inc. share count unchanged in Q4 2016.
Concert Pharmaceuticals, Inc. made up ﹤0.01% of BlackRock Investment Management's portfolio in Q4 2016, its #2872 holding.
BlackRock Investment Management first reported a position in Concert Pharmaceuticals, Inc. in Q1 2014 and has held it in 12 quarters since.
BlackRock Investment Management's Concert Pharmaceuticals, Inc. position peaked at $1.04M in Q4 2015.
89 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q4 2016.

Based on BlackRock Investment Management's 13F filing for Q4 2016, filed 10 Feb 2017.